Nomic develops the proprietary nELISA platform, enabling massive multiplexing, full quantification, and cost-efficient protein profiling. The platform currently offers a comprehensive solution for inflammation research and high-throughput quantification of hundreds of secreted proteins. Nomic serves over 75 customers across top-10 pharma, innovative biotechs, and research institutes and has collectively profiled more than 400,000 samples. To meet surging demand the company has built industrial-scale facilities offering high throughput and fast turnaround for protein profiling services. With new capital Nomic plans to expand commercial operations, further advance the nELISA platform, and broaden its offerings to cover proteins across the entire proteome. Leadership cited in the article includes CEO and co‑founder Milad Dagher and board member Byron Hewett. Nomic Bio is building the nELISA, a next-generation ELISA platform that leverages DNA nanotechnology, spectral multiplexing, and automation to enable massively scalable, multiplexed protein quantification. The nELISA is designed to deliver high throughput and cost-efficiency while maintaining the sensitivity and specificity of traditional ELISAs and to integrate into existing biological workflows. Nomic has worked with select partners across the pharmaceutical and biotech industry, from mid-sized biotechs to top-ten pharma, to advance drug discovery. The company will use new capital to grow teams in Montreal and Boston and to expand access to the platform. Planned operational goals include increasing profiling capacity to 100,000 samples a quarter by Q2 2022, scaling the nELISA to 500 on-boarded proteins, and beginning development of new modalities such as post-translational modification identification. The company has raised over US$21 million to date following its recent financing.

Total raised

$59M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2024